

# International protocol for the treatment of childhood anaplastic large cell lymphoma (ALCL)

<b>Submission date</b> 01/07/2001	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/07/2001	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 19/10/2018	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Denise Williams

**Contact details**  
Cambridge University Hospitals NHS Foundation Trust  
Children's Service  
Box No 181  
Addenbrookes Hospital  
Hills Road  
Cambridge  
United Kingdom  
CB2 2QQ  
+44 (0)1223 216 878  
denise.williams@addenbrookes.nhs

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT00006455

**Protocol serial number**  
NHL 2000/06

# Study information

## Scientific Title

International protocol for the treatment of childhood anaplastic large cell lymphoma (ALCL)

## Study objectives

Not provided at time of registration

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Lymphoma (non-Hodgkin's)

## Interventions

Four arms:

Arm one: MTX (1 g/m<sup>2</sup>) over 24 hours with intrathecal

Arm two: MTX (1 g/m<sup>2</sup>) over 24 hours with intrathecal and Vinblastine for one year

Arm three: MTX (3 g/m<sup>2</sup>) over three hours without intrathecal

Arm four: MTX (3 g/m<sup>2</sup>) over three hours without intrathecal and Vinblastine for one year

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

MTX, vinblastine

## Primary outcome(s)

Not provided at time of registration

## Key secondary outcome(s)

Not provided at time of registration

## Completion date

31/12/2006

# Eligibility

## Key inclusion criteria

1. ALCL diagnosed by local pathologist
2. Slides available for national review
3. Aged <22 years
4. No previous treatment
5. Appropriate ethical approval

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Child

## Upper age limit

22 years

## Sex

All

## Key exclusion criteria

Not applicable

## Date of first enrolment

01/04/2000

## Date of final enrolment

31/12/2006

# Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

Cambridge University Hospitals NHS Foundation Trust

Cambridge

United Kingdom

CB2 2QQ

# Sponsor information

## Organisation

Cancer Research UK (CRUK) (UK)

## ROR

<https://ror.org/054225q67>

# Funder(s)

## Funder type

Charity

## Funder Name

Cancer Research UK

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

## Funder Name

United Kingdom Children's Cancer Study Group (UKCCSG)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2010		Yes	No

<a href="#">Results article</a>	results	26/05/2011	Yes	No
<a href="#">Results article</a>	results	01/07/2011	Yes	No
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No
<a href="#">Plain English results</a>			No	Yes